Hopkinton, Mass.-based Spring Bank Pharmaceuticals Inc. appointed Timothy Clackson as an independent member of its board.
Clackson was most recently president of research and development at Ariad Pharmaceuticals Inc., which was acquired by Takeda Pharmaceutical Co. Ltd.
Clackson's experience in biopharmaceutical development will help Spring Bank in the development of its hepatitis B treatment inarigivir, the company said in a news release.
